|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:methoxy_polyethylene_glycol-epoetin_beta
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2007
|
|
gptkbp:ATCCode
|
gptkb:B03XA03
|
|
gptkbp:CASNumber
|
gptkb:945076-68-4
|
|
gptkbp:chemicalClass
|
erythropoietin analog
|
|
gptkbp:contraindication
|
uncontrolled hypertension
hypersensitivity to the active substance
|
|
gptkbp:developedBy
|
gptkb:Roche
|
|
gptkbp:drugClass
|
erythropoiesis-stimulating agent
|
|
gptkbp:form
|
solution for injection
vial
pre-filled syringe
|
|
gptkbp:halfLife
|
~133 hours (subcutaneous)
~139 hours (intravenous)
|
|
gptkbp:hasCompany
|
gptkb:F._Hoffmann-La_Roche_AG
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mircera
|
|
gptkbp:indication
|
treatment of symptomatic anemia in adult patients with chronic kidney disease
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
erythropoiesis-stimulating agent
|
|
gptkbp:monitors
|
hemoglobin levels
|
|
gptkbp:notToBeFrozen
|
true
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
patients not on dialysis
patients on dialysis
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:regulates
|
red blood cell production
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
edema
headache
hypertension
arthralgia
upper respiratory tract infection
|
|
gptkbp:storage
|
refrigerate (2°C–8°C)
|
|
gptkbp:tradenameOf
|
gptkb:methoxy_polyethylene_glycol-epoetin_beta
|
|
gptkbp:usedFor
|
gptkb:anemia
anemia due to chronic kidney disease
|
|
gptkbp:bfsParent
|
gptkb:epoetin_beta
gptkb:Vifor_Pharma
gptkb:F._Hoffmann-La_Roche_AG
|
|
gptkbp:bfsLayer
|
7
|